Memantine Ciclum (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist of the NMDA receptor. By blocking excessive calcium entry through the receptor’s ion channel, it reduces neuronal excitotoxicity while allowing normal synaptic activity needed for learning and memory.

The dosage of Memantine Ciclum is determined by the prescribing clinician based on the patient’s condition, age, renal function and other factors. The prescriber will set the appropriate dose and titration schedule.

Safety data for memantine in pregnancy and lactation are limited. It is classified as a drug with unknown risk, so it should only be used if the potential benefit outweighs any possible risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas cholinesterase inhibitors (e.g., donepezil) increase acetylcholine levels. Memantine is often used alone or as add‑on therapy for patients who do not respond adequately to cholinesterase inhibitors, offering a different mechanism of neuroprotection.

Memantine Ciclum should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed.

Memantine Ciclum is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, according to the prescribing information provided by the healthcare professional.

Serious adverse events, although rare, include seizures, severe hypotension, cardiac arrhythmias, hepatic dysfunction and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for any new or worsening neurological or cardiac symptoms.

Memantine is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA‑receptor antagonists.